Search results for "APR"
showing 10 items of 2648 documents
The influence of age at slaughter and litter size on some quality traits of kid meat
2002
Abstract To study variations in the carcass characteristics of Girgentana kids slaughtered at 25 or 35 days of age and litter size (single or twin), 27 male kids were slaughtered and body components, carcass joints, pelvic limb tissue composition, meat fatty acid composition and M. longissimus dorsi (LD) colour were evaluated. Girgentana kids slaughtered at 35 days had greater live weights (6.4 kg versus 5.0 kg; P ≤0.01), carcass weights (4.5 kg versus 3.6 kg; P ≤0.01), muscle contents (57.6% versus 54.9%; P ≤0.01) but similar dressing percentages (70.1% versus 70.6%) as compared to kids slaughtered at 25 days. Twin kids had a higher muscle percentage (57.3% versus 55.2%; P ≤0.05) and simil…
Use of weaning concetrate in the feeding of suckling kids: effects on meat quality
2006
A study was conducted to investigate the effect of a feeding supplementation with starter concentrate on “Capretto” meat production and its qualitative characteristics. To this end, 31 Girgentana kids, slaughtered at 59 days of age from two feeding groups (concentrate group (CG) and milk group (MG)) were utilised. Carcass measurements (body components, carcass joints, pelvic limb tissue composition, meat fatty acid composition and M. longissimus dorsi (LD) physical characteristics), body weight at birth, and at slaughter, were evaluated. The effect of concentrate supplementation did not influence the slaughter weight, slaughter and dissection data, tissue composition and meat chemical compo…
Effects of litter size and sex on meat quality traits of kid meat
2004
The influence of litter size and sex on meat quality traits was investigated using 40 Nebrodi kids slaughtered at 47 days of age. Carcass measurements (body components, carcass joints, pelvic limb tissue composition, meat fatty acid composition and M. longissimus dorsi (LD) colour), body weight at birth and at slaughter were evaluated. Nebrodi kids had a low body weight at birth, with significant differences between male and female (4.1 kg versus 3.9 kg) and between single and twin (4.2 kg versus 3.8 kg). Male kids were heavier at birth and at slaughter, however, females had a higher percentage of kidney and pelvic fat (2.1% versus 1.5% of the right side; P < 0.01). Both males and females, …
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – …
2013
International audience; Background & AimsIn phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated cirrhotics treated in the French Early Access Programme.Methods674 genotype 1 patients, prospectively included, received 48 weeks of triple therapy. The analysis is restricted to 497 patients reaching week 16.ResultsA high incidence of serious adverse events (40.0%), and of death and severe complications (severe infection or hepatic dec…
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. : Triple therapy in HCV geno…
2014
International audience; BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and compensated cirrhosis who did not respond to a prior course of peginterferon and ribavirin (44.3% relapsers or patients with viral breakthrough, 44.8% partial responders, and 8.0% null responders) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks. We assessed percentages of patients with sustained viral respo…
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
2015
Background and rational. Telaprevir-based therapy (TBT) has been extensively evaluated in clinical trials. So we designed a study to compare the efficacy and safety of TBT between patients with moderate fibrosis and those suffering from advanced fibrosis in clinical practice. A multicenter observational and ambispective study was conducted. It included 582 patients with chronic hepatitis C genotype 1, 214 with fibrosis F2, and 368 with F3/F4 (F3: 148; F4: 220). Results. The mean patient age was 55 years, 67% male. Type of prior response was 22% naive, 57% relapsers, and 21% partial/null responders, 69% had high viral load (> 800,000 IU/mL). HCV genotypes were 1a (19%), 1b (69%), and 1 (12%)…
Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir.
2013
Haemophagocytic syndrome (HS) is a rare disease that is often fatal despite treatment. HS is characterized by fevers, lymphadenopathy, hepatosplenomegaly, cytopenias and hyperferritinaemia due to deregulated activation and proliferation of macrophages, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes, and their hematopoietic precursors throughout the reticuloendothelial system. Mycobacterium tuberculosis-associated HS is a rare and underdiagnosed association with only 39 cases reported. We describe a case of HS associated with disseminated Mycobacterium tuberculosis in the setting of post-liver transplantation anti-hepatitis C therapy with pegylated interferon (p…
Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis
2021
Objective Treatment of recalcitrant moderate-to-severe psoriasis can be challenging. Combination therapy of biologics and immunosuppressive agents can be a new strategy for treating therapy-resistant cases with comorbidities, where many systemic medications are contraindicated. Case presentation We report a case of a 62-year-old diabetic man with a 30-year history of severe plaque psoriasis and psoriatic arthritis with cirrhosis and diabetic nephropathy that was treated successfully in combination with apremilast and etanercept after multiple previous unsuccessful treatment attempts. Conclusion There are no data supporting the combination of apremilast and etanercept in the management of re…
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
2014
Introduction: On-treatment HCV RNA measurements are crucial for the prediction of a sustained virological response (SVR) and to determine treatment futility during protease inhibitor-based triple therapies. In patients with advanced liver disease an accurate risk/benefit calculation based on reliable HCV RNA results can reduce the number of adverse events. However, the different available HCV RNA assays vary in their diagnostic performance. Aim: To investigate the clinical relevance of concordant and discordant results of two HCV RNA assays during triple therapy with boceprevir and telaprevir in patients with advanced liver fibrosis/cirrhosis. Methods: We collected on-treatment samples of 1…
Kuršu ķoniņi
1876
3 noraksti no tiesu aktiem par kuršu ķoniņiem (1876.-1892.)